BioAge is a platform-driven, clinical-stage biotechnology company that is mapping human aging to develop a pipeline of therapies that treat disease and extend healthy lifespan. Our proprietary platform encompasses >65M molecular measurements spanning 45+ years of human aging and unlocks a universe of novel biological insights and druggable mechanisms for age-related disease. Our growing clinical-stage portfolio includes BGE-105, a first-in-class apelin receptor agonist that prevented muscle atrophy in a Ph1b study of older volunteers at bedrest. We are developing BGE-105 in parallel for ICU-related atrophies and for muscle preservation during GLP-1 weight loss therapy. The portfolio also includes novel internally discovered NLRP3 inhibitors for neurodegenerative and ocular diseases driven by inflammation. Our mission is to develop therapies that change the nature of aging and provide patients with years more healthy time. To date, BioAge has raised $127M from Andreessen Horowitz, Kaiser Foundation Hospitals, and others.

BioAge offers a comprehensive compensation package, comprehensive health and wellness benefits (medical, dental, and vision insurance), childcare and fertility benefits, and a 401(k) retirement savings plan with matched employer contributions. We pride ourselves on giving employees many opportunities for career development, including a generous annual budget for continued learning and dedication to training and skill development.

At BioAge, everyone matters, and we embrace diversity and differences while we learn from each other. We are an equal opportunity employer. BioAge prohibits discrimination and harassment of any type and affords equal employment opportunities to employees and applicants without regard to race, color, religion, sex, national origin, disability status, protected veteran status, or any other characteristic protected by law. BioAge conforms to the spirit as well as the letter of all applicable laws and regulations.


AME Cloud Ventures

Andreessen Horowitz

Felicis

Pear VC

Redpoint

Bossanova Investimentos

Caffeinated Capital

Kaiser Foundation Hospitals

Elad Gil

Ling Wong

BioAge Labs

BioAge is pleased to announce plans to initiate a Phase 2 trial of our apelin receptor agonist azelaprag co-administered with tirzepatide for treatment of obesity. Under the terms of an agreement signed yesterday, Eli Lilly and Company will provide tirzepatide for the study, and Lilly’s Chorus organization will advise and assist BioAge on trial design and execution. The trial, planned to start in mid-2024, is designed to assess whether this drug combination can achieve increased overall weight loss with improved body composition.

https://lnkd.in/gnpq_Juh

👇🏼 Keep reading for more background & why we’re excited for the trial:

• Azelaprag is an oral drug for the future of obesity therapy: Co-administration has the potential to achieve best-in-class weight loss with next-generation oral incretins currently in the pipeline, whose performance lags behind injectables. Our goal is 20–25% healthy weight loss with a completely oral drug combination.

• We are collaborating with a global leader in obesity: We are thrilled to work directly with the clinical development experts at Chorus and benefit from Lilly’s experience in obesity drug development. We are proud to collaborate with Lilly in one of their most important and competitive areas. 

• Our promising preclinical data points to greater — and healthier — weight loss: In diet-induced obese (DIO) mice, co-administration with azelaprag substantially increased weight loss achieved on tirzepatide alone. In addition, the combination normalized body composition to that of lean controls and decreased blood glucose levels

• Apelin signaling has been demonstrated to have multiple benefits for energy metabolism — and in our Phase 1b trial, azelaprag promoted muscle metabolism and protein synthesis while being well tolerated in healthy volunteers. 	

• The planned trial will advance BioAge’s mission of extending healthy lifespan in a new indication: Treating obesity has the potential to prevent or delay multiple diseases of aging for a large segment of the population.


Learn more about azelaprag, the apelin pathway, and obesity on our website:
https://lnkd.in/gSRkyM-t


BioAge is proud to sponsor Longevity Global’s 2024 SF kickoff event on Tuesday, Jan 30: afternoon co-working at the beautiful Savills space in downtown San Francisco, followed by lightning pitches and networking over drinks and food. Bring your laptop and co-work with friends (1–5 pm), and then pitch your longevity idea in the early evening (5–7:30).

See invite for details: https://lu.ma/f1mtzklu
Registration is free for first-time attendees of Longevity SF events.

See you there!

We got 2024 off to a great start with BioAge’s annual panel discussion & reception during JPM Healthcare Week. In a conversation moderated by BioAge CEO Kristen Fortney, panelists Tracey McLaughlin (Professor, Stanford University School of Medicine), Rob Myers, MD (CMO, OrsoBio), Michael Davidson (CEO, NewAmsterdam Pharma), and Axel Haupt (Senior Vice President, Diabetes Clinical Development, Eli Lilly and Company) shared their thoughts on our theme of “Extending human healthspan: Obesity, metabolism, and aging”.

Key takeaways from their conversation:

✅ Many pathways link obesity, metabolic disorders, and aging — and targeting these common pathways may have benefits for treating chronic disease.

✅ Emerging drug targets like apelin, FGF21, CETP inhibitors, and others have effects on aging pathways as well as specific diseases like obesity, diabetes, and CVD. Combination therapies may have synergistic benefits.

✅ Challenges in studying drugs for prevention include long trial durations, the need for large sample sizes, identification of appropriate biomarkers, and lack of reimbursement incentives. Regulators and stakeholders need to collaborate on solutions.

✅ Biomarkers are advancing: lipids and CRP have potential for tracking metabolic health; advanced imaging may eventually be accepted for showing benefits on atherosclerosis; and Alzheimer's disease trials are moving towards biomarker-based approvals.

✅ Key upcoming readouts will provide more evidence on whether incretins and new mechanisms can improve cardiovascular and kidney outcomes. Studies on preserving muscle mass with weight loss and combination approaches for obesity are important.

✅ Precision medicine approaches, targeting treatments based on disease subtypes and underlying physiology, will come to the fore as the cardiometabolic space attracts more attention and resources. 

Many thanks to our brilliant panelists — and to all who attended and created such an enjoyable evening!

📸 Action shot! At abcam's 2023 Innate Sensing & Signaling in Immunology meeting in Boston this week, BioAge scientists Kevin Wilhelmsen, Sarah Tronnes, and Aditi Deshpande presented a poster on our novel class of NLRP3 inflammasome inhibitors, which we are developing for inflammatory and age-related diseases. 

BioAge’s AI-driven discovery platform revealed that NLRP3 levels rise with age and are positively correlated with all-cause mortality. To identify novel NLRP3 inhibitors, we screened billions of molecules in a DNA-encoded library (DEL) for compounds that bind purified NLRP3 protein, yielding drug-like compounds that functionally inhibit the NLRP3 inflammasome in vitro with comparable or superior potency relative to publicly known inhibitors.

https://lnkd.in/gmUffkJD

Elevian is a biotechnology company focused on developing drugs to target aging and age-related diseases.

Elevian

Rubedo is a biotechnology company specializing in developing treatments for aging-related conditions.

Rubedo

Alkahest is a biotechnology company engaged in researching and developing therapies for age-related diseases.

Alkahest

Revitope Oncology Inc is a clinical-stage biotechnology company focused on developing novel cancer therapies.

Revitope Oncology Inc

Surrozen Inc is a biotechnology company specializing in regenerative medicine and tissue repair.

Surrozen Inc

BioAge Labs is focused on harnessing the biology of human aging to develop new therapies for metabolic diseases. Their lead program, azelaprag, aims to be a first and best-in-class oral weight loss therapy co-administered with incretin drugs to achieve injectable-like total weight loss. The company's human-first discovery platform analyzes proprietary multi-omics data captured over decades to identify the molecular mediators of aging and disease. Their mission is to develop a pipeline of treatments that extend healthy lifespan by targeting the molecular causes of aging.

Associate Director

Principal Scientist

Senior Scientist

Scientist

Postdoctoral Fellow

Graduate Student Researcher

Ph.D. Scientist & Small Team Leader in Drug Discovery

Yong Pan

Member Board Of Directors

Board Member, Chair of Compensation Committee

Board Member, Chair of Audit Committee & Member of Nom & Gov Committee

Investment Advisory Board of the Michigan Biomedical Venture Fund

Chief Executive Officer & Board Member

Biotech Executive & Board Member

Rekha Hemrajani

Director, Head of Statistical Programming and Data Management

Associate Director of Statistical Programming

Senior Manager of Statistical Programming

Principal Statistical Programmer (Sr. Mgr.)

Clinical Programmer

Senior Programmer

Statistical Programmer II

Statistical Programmer I

SAS Clinical Programmer

Director, Head of Statistical Programming and Data Management at BioAge Labs

Eric Wang

Director - In Vivo Biology

Associate Director, In Vivo Operations

Vivarium Manager

Production Supervisor

Associate Supervisor

Technologist

Lake Berryessa Outreach Intern

Environmental Department Student Intern

Director - In Vivo Biology at BioAge Labs, MBA, LATG

Matt Banicki

Director of Biology

Associate Director of Biology

Assistant Adjunct Professor

Principal Investigator / Project Leader

Postdoctoral Scholar

Postdoctoral Research Fellow

Director of Biology at BioAge Labs

Kevin Wilhelmsen

Chief Strategy Officer

VP, Strategy & Business Operations

Chief of Staff

Manager

Senior Consultant (Project Leader)

Consultant (Project Leader)

Senior Life Sciences Specialist

Life Sciences Specialist

Chief Strategy Officer, BioAge Labs

BJ Sullivan

COO, co-founder

Member Board of Directors

Chief Medical Officer

Assistant Professor & Academic Physician

Clinical Fellow and Research Fellow, Computational Biology & Molecular Epidemiology

Pathology Resident

COO, co-founder at BioAge Labs

Eric Morgen

Associate Director, Business Development

Associate Director, Business Development & Licensing

Business Development and Alliance Management Manager

Scientific Consultant

Scientist II

Competitive Intelligence Consultant, Oncology

Biotech | Business Development | Partnerships | Innovation & Strategy

Ivy Chen

Associate Director, Quality Systems

Senior Manager Quality, Document Control and Training

Associate Director Quality Assurance

Quality Manager

Senior Manager Enterprise Document Management Systems

Manager Archive Services: Document Control and Central Records

Quality Assurance Manager, Document Control Manager, MFG. IPT Core Services Manager

Document Control

Associate Director, Quality Systems, BioAge Labs

Wanda Brown

Head of R and D and Chief Medical Officer

Pharma and Biotech Consultant

Executive Vice President Research and Development

Senior Vice President of Research and Development and Chief Medical Officer

Vice President, Clinical Pharmacology and Early Development

Vice President Endocrine and Immunology

Venture Head, Immunology

Head of R and D and Chief Medical Officer, BioAge Laboratories

Paul Rubin

Director of Regulatory Affairs

Owner, Regulatory Affairs Consultant

Associate Director, Regulatory Affairs

Senior Manager Regulatory Affairs

Senior Regulatory Affairs Specialist

Principal Regulatory Affairs Specialist

Director of Regulatory Affairs at BioAge Labs

Christopher Perman

Chief Development Officer

Biopharma Executive and Drug Development Consultant

Founding Member

Senior Vice President Development Operations

Senior Vice President, Clinical Operations and Patient Affairs

VP Clinical Operations and Data Assessment

VP Clinical Operations

Senior Director, Development Planning and Operations

Senior Director Clinical Operations

Founding Principal and Chief Operations Officer

Associate Director Clinical Development

Senior Clinical Program Manager

Senior Clinical Research Associate

Ann Neale

Director, Clinical Science

Biotech Consulting

Physician

Associate Medical Director

Family Medicine Resident

Program Counsellor, Human Biology Program

Physician, Biotech Drug Development

Ling Chen

Sr. Director, Program and Portfolio Management

Head of Program Management & Clinical Supply Operations

Director, Head of Cell Therapy Clincial Demand Planning

Director, Global Trial Management

Juno Therapeutics, Inc.

Senior Program Manager

Program Manager

Program and Portfolio Management Leader

Jessica Hussell

Senior Director, Program, Portfolio, and Alliance Management

Director Program Management

Associate Director, Global Cell Therapy Franchise, Liso-cel Project Manager

Sr. Manager, Project Management - Cellular Therapy

Senior Medical Writer

Medical Writer II

Medical Writer I

Regulatory Coordinator

Study Coordinator

Clinical Study Assistant/Outpatient Clinic Representative

Candace Larson

Director, Internal Products

Associate Director, Program Management

Vice President Operations

Full Stack Engineer

Co-Founder

Product Manager

Project Manager

Director at BioAge Labs

Kia Winslow

Head of Information Technology

Vice President of IT

Executive Director, Head of IT

Senior Director, Head of IT

Director IT Operations

Associate Director of IT Projects

Senior Manager, IT - Manufacturing & Lab Technologies

Manager, IT - Enterprise Architecture

Supervisor, IT Systems Engineering

Operations Supervisor, IT

IT Support Technician

Intern

Information Technology Leader | Driving Innovation | Empowering Success

Nick Grundy

Senior Director, Process Chemistry

Lecturer in Chemistry

Vice President of Chemistry and Biochemistry

Senior Director, Chemistry, Manufacturing and Controls

Chief Executive Officer

Executive Director

Senior Director, Process Chemistry BioAge Labs Inc.

Kim Albizati

Chief Business Officer and Head of Brain Aging

Business Development and Strategy Consulting

Business Development Advisor

Chief Business Officer

CBO and Head of Brain Aging | Company Builder | PhD MBA

Peng Leong

news impact assignment basic	general	Feb 13, 2024 8:47 PM	1ab20a89
public peers	general
news daily refresh	general	Jul 25, 2024 12:00 PM	7e13611f
news processing daily refresh	general	May 21, 2024 2:40 AM	2bfb0b11
news impact assignment daily	general	May 21, 2024 6:14 PM	950b6d0d
news processing basic	general	Feb 13, 2024 8:47 PM	2660a991
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	1a9aab32
crunchbase profile	general	Nov 27, 2024 1:31 PM	70c05de2
li profile	general	Feb 13, 2024 8:47 PM	be929b4f
translate crunchbase fundingrounds	general
peers	general	Feb 13, 2024 8:47 PM	a11c1c09
news basic	general	Feb 13, 2024 8:47 PM	610d1dd4
bundesanzeiger	filings
financials download nd	financials
private financials	financials

BIOA

COM:BIOAGELABS

BioAge Labs

Last Close

19.14

22/11 21:00

Market Cap

220.11M

Beta: -

Volume Today

157.82K

Avg: -